FDA Accepts Supplement for VYEPTI (EPTINEZUMAB-JJMR) by Lundbeck
The FDA has accepted a supplemental application for VYEPTI, an anti-CGRP therapy for migraine.
Asset / Drug
Drug and asset intelligence for Lundbeck with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.